share_log

科濟藥業-B：翌日披露報表

CARSGEN-B: Next Day Disclosure Return

Hong Kong Stock Exchange ·  Jun 6 09:28
Summary by Moomoo AI
科濟藥業控股有限公司（科济药业-B）於2024年6月6日提交了翌日披露報表，披露了公司股份購回的詳細情況。根據報表，公司於2024年5月31日、6月4日及6月6日分別購回了400,000股、60,500股和670,000股普通股，合計購回1,130,500股，佔已發行股份的0.196%。最近一次購回發生在2024年6月6日，當日購回670,000股，每股價格介乎HKD 5.71至HKD 5.86，總額約為HKD 3,883,064.8。公司確認，所有購回行動均獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
科濟藥業控股有限公司（科济药业-B）於2024年6月6日提交了翌日披露報表，披露了公司股份購回的詳細情況。根據報表，公司於2024年5月31日、6月4日及6月6日分別購回了400,000股、60,500股和670,000股普通股，合計購回1,130,500股，佔已發行股份的0.196%。最近一次購回發生在2024年6月6日，當日購回670,000股，每股價格介乎HKD 5.71至HKD 5.86，總額約為HKD 3,883,064.8。公司確認，所有購回行動均獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
On June 6, 2024, SciClone Pharmaceuticals Holding Limited (Sciclone Pharmaceuticals-B) submitted the next day disclosure statement, disclosing the details of the company's share repurchase. According to the statement, the company repurchased 400,000 shares, 60,500 shares, and 670,000 ordinary shares on May 31, June 4, and June 6, 2024, respectively, with a total repurchase of 1,130,500 shares, accounting for 0.196% of the issued shares. The latest repurchase occurred on June 6, 2024, when 670,000 shares were repurchased at a price between HKD 5.71 and HKD 5.86 per share, for a total amount of approximately HKD 3,883,064.8. The company confirmed that all repurchase actions were approved by the board of directors and comply with the relevant requirements of the listing rules of The Stock Exchange of Hong Kong Limited.
On June 6, 2024, SciClone Pharmaceuticals Holding Limited (Sciclone Pharmaceuticals-B) submitted the next day disclosure statement, disclosing the details of the company's share repurchase. According to the statement, the company repurchased 400,000 shares, 60,500 shares, and 670,000 ordinary shares on May 31, June 4, and June 6, 2024, respectively, with a total repurchase of 1,130,500 shares, accounting for 0.196% of the issued shares. The latest repurchase occurred on June 6, 2024, when 670,000 shares were repurchased at a price between HKD 5.71 and HKD 5.86 per share, for a total amount of approximately HKD 3,883,064.8. The company confirmed that all repurchase actions were approved by the board of directors and comply with the relevant requirements of the listing rules of The Stock Exchange of Hong Kong Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more